Cystic Fibrosis & GI

GI manifestations of cystic fibrosis are increasingly important as patients live longer with CFTR modulator therapy. The session covers pancreatic insufficiency and PERT optimisation, CFTR modulators (Trikafta/Kaftrio) and their GI effects including weight gain and the new nutrition challenges, CF liver disease and surveillance, distal intestinal obstruction syndrome (DIOS) management, CF-related diabetes, and the rising obesity-with-CF phenomenon. Discussion addresses CF transplant nutritional preparation, fat-soluble vitamin replacement, microbiome alterations in CF, the cancer screening implications of longer CF survival, transition from pediatric to adult CF care, and the equity considerations as CFTR modulators remain inaccessible in many low- and middle-income countries.